1701 — China Chemical & Pharmaceutical Co Income Statement
0.000.00%
Last trade - 00:00
- TWD6.49bn
- TWD9.48bn
- TWD8.57bn
- 60
- 53
- 19
- 37
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 7,970 | 8,181 | 7,949 | 8,457 | 8,575 |
Cost of Revenue | |||||
Gross Profit | 2,976 | 2,969 | 2,865 | 3,088 | 3,140 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 7,595 | 7,760 | 7,525 | 8,077 | 8,344 |
Operating Profit | 375 | 421 | 424 | 379 | 231 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 446 | 658 | 659 | 589 | 391 |
Provision for Income Taxes | |||||
Net Income After Taxes | 385 | 560 | 516 | 479 | 324 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 385 | 557 | 518 | 478 | 322 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 385 | 557 | 518 | 478 | 322 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 1.29 | 1.85 | 1.72 | 1.59 | 1.07 |
Dividends per Share |